Omega Fund Management
$186M 13F equity value
11 Holdings
Quarter ended June 30, 2026
The latest 13F on file for Omega Fund Management covers the quarter ended June 30, 2026. Institutional managers report holdings quarterly to the SEC, so each filing is a snapshot of positions held on that date.
Top Holdings
| Ticker | Company | Shares | Value | Weight |
|---|---|---|---|---|
| BCAX | Bicara Therapeutics Inc. | 1,822,150 | $54M | 29.1% |
| NUVB | Nuvation Bio Inc. | 8,081,089 | $46M | 24.7% |
| KMTS | Kestra Med Technologies Ltd | 1,022,149 | $26M | 14.0% |
| BBOT | BridgeBio Oncology Therapeutics Inc. | 3,289,661 | $25M | 13.5% |
| BBNX | Beta Bionics Inc. | 1,316,183 | $21M | 11.1% |
| ALMS | Alumis Inc. | 241,255 | $7M | 3.7% |
| SANA | Sana Biotechnology, Inc. | 843,750 | $3M | 1.6% |
| IMA | ImageneBio, Inc. | 455,361 | $3M | 1.4% |
| ENGN | enGene Holdings Inc. | 876,357 | $2M | 0.8% |
| ODTX | Odyssey Therapeutics Inc. | 2,893 | $54,128 |
Track Omega Fund Management's 13F portfolio: $186M in reported holdings, 11 positions. Top holdings and quarterly changes on SentiSense.
This page is powered by the SentiSense API: GET /api/v1/institutional/institution/{slugOrCik}